Endo International plc (ENDP) PT Raised to $17 at Deutsche Bank

Go back to Endo International plc (ENDP) PT Raised to $17 at Deutsche Bank

Endo International (ENDP): Vasopressin Headlines Likely Worse than Reality - Citi

August 13, 2018 1:30 PM EDT

Citi analyst Liav Abraham weighed in on Endo International plc (NASDAQ: ENDP) following news Athenex lanched a compounded Vasopressin. Abraham said the headline is likely worse than reality.

The firm reiterated a Buy rating and price target of $19.00

For an analyst... More

Endo International (ENDP) Weakness on Compounded Vasopressin Launch Bears Watching FDA Action - RBC

August 13, 2018 11:39 AM EDT

The downside in Endo International (NASDAQ: ENDP) (-2.7%) is related to news Athenex (NASDAQ: ATNX) announced that it had launched compounded Vasopressin injection (i.e. Vasostrict) in ready-to-use premix IV bags via Section 503B of the DQSA, RBC... More

RBC Capital Upgrades Endo International plc (ENDP) to Outperform on Cycle Up-Turn

August 13, 2018 4:51 AM EDT

(Updated - August 13, 2018 7:15 AM EDT)

(updated to add analyst comments)

RBC Capital analyst Randall Stanicky upgraded Endo International plc (NASDAQ: ENDP) from Sector Perform to Outperform with a price target of $26.00 (from $8.00).

Stanicky said the upgrade is in... More